This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:


peer-reviewed publication

reputable news agency


Dapagliflozin cuts cardiovascular events in patients with heart failure, T2D

Dapagliflozin cuts cardiovascular events in patients with heart failure, T2D

For patients with heart failure and type 2 diabetes (T2D), dapagliflozin does not reduce urinary albumin-to-creatinine ratio (UACR) but does reduce some cardiovascular events, according to a study published online Nov. 27 in eClinicalMedicine.

Fumiki Yoshihara, from the National Cerebral and Cardiovascular Center in Osaka, Japan, and colleagues conducted a multicenter, randomized trial that enrolled patients at 18 in Japan to examine the effects of dapagliflozin on UACR in patients with heart failure and T2D. Eligible participants were randomly assigned to a dapagliflozin or in a 1:1 ratio (146 and 148 patients, respectively).

At the end of the observation period, 107 (87.7 percent) were taking 5 mg dapagliflozin daily. The researchers observed no significant difference in the primary outcome of changes in UACR from baseline after a two-year observation between the dapagliflozin and control groups. Among the secondary end points, the dapagliflozin group had a larger mean decrease in left ventricular end-diastolic dimensions as one of the echocardiographic parameters. Compared with the control group, the dapagliflozin group had the composite end point less often, defined as cardiovascular death or hospitalization for , hospitalization for heart failure events, hospitalization for all causes, and an additional change in prescriptions for in a two-year observation.

"The results obtained on the primary end point revealed no significant difference in renal dysfunction judged by UACR between the dapagliflozin and control groups, which is in contrast to previous findings from three randomized controlled trials," the authors write.

Several authors disclosed ties to biopharmaceutical companies, including AstraZeneca and Ono Pharmaceuticals, which partially funded the study.

More information: Fumiki Yoshihara et al, DAPagliflozin for the attenuation of albuminuria in Patients with hEaRt failure and type 2 diabetes (DAPPER study): a multicentre, randomised, open-label, parallel-group, standard treatment-controlled trial, eClinicalMedicine (2023). DOI: 10.1016/j.eclinm.2023.102334

Journal information: EClinicalMedicine

Copyright © 2023 HealthDay. All rights reserved.

Citation: Dapagliflozin cuts cardiovascular events in patients with heart failure, T2D (2023, December 30) retrieved 18 April 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Dapagliflozin suppresses cardiovascular events in patients with chronic heart failure, type 2 diabetes mellitus: Study


Feedback to editors